2024
Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial.
Hutchison R, Fraser K, Yang M, Fox T, Hirschhorn E, Njingti E, Scott D, Bedell B, Kistner K, Cedarbaum J, Evans K, Graham D, Martarello L, Mollenhauer B, Lang A, Dam T, Beaver J. Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial. Neurology 2024, 102: e209137. PMID: 38315945, DOI: 10.1212/wnl.0000000000209137.Peer-Reviewed Original ResearchMeSH KeywordsAlpha-SynucleinAntibodies, MonoclonalAntiparkinson AgentsBiomarkersDisease ProgressionDopamineDouble-Blind MethodHumansParkinson DiseaseConceptsDisease progressionDopaminergic deficitNeurofilament light chain levelsNigrostriatal dopamine pathwayDopamine transporter SPECTTerminated due to lackStriatal dopaminergic deficitsLight chain levelsClinical disease progressionEvidence of dopaminergic deficitParkinson's diseaseEvaluate disease severityBiomarker measurementsEarly Parkinson's diseaseStriatal binding ratiosDevelopment of therapiesStatistically significant differenceScale total scoreBiomarker resultsDouble-blindPlacebo-controlledUnified Parkinson's Disease Rating Scale total scoreDopamine pathwayClinical trialsPrimary outcome
2022
Trial of Cinpanemab in Early Parkinson’s Disease
Lang A, Siderowf A, Macklin E, Poewe W, Brooks D, Fernandez H, Rascol O, Giladi N, Stocchi F, Tanner C, Postuma R, Simon D, Tolosa E, Mollenhauer B, Cedarbaum J, Fraser K, Xiao J, Evans K, Graham D, Sapir I, Inra J, Hutchison R, Yang M, Fox T, Budd Haeberlein S, Dam T. Trial of Cinpanemab in Early Parkinson’s Disease. New England Journal Of Medicine 2022, 387: 408-420. PMID: 35921450, DOI: 10.1056/nejmoa2203395.Peer-Reviewed Original ResearchMeSH KeywordsAlpha-SynucleinAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntiparkinson AgentsDouble-Blind MethodHumansParkinson DiseaseTreatment OutcomeConceptsEarly Parkinson's diseasePrimary end pointSecondary end pointsWeek 52Parkinson's diseaseEnd pointControl groupUnified Parkinson's Disease Rating Scale (UPDRS) total scoreDisease pathogenesisHuman-derived monoclonal antibodiesΑ-synucleinCommon adverse eventsPhase 2 trialDisease-modifying treatmentsMDS-UPDRS scoresLack of efficacyDAT SPECT imagingAdjusted mean differenceMovement Disorder SocietyParkinson's disease pathogenesisScale total scoreAdverse eventsIntravenous infusionDAT-SPECTDisease progression
2018
Elephants, Parkinson's Disease, and Proof‐of‐Concept Clinical Trials
Cedarbaum JM. Elephants, Parkinson's Disease, and Proof‐of‐Concept Clinical Trials. Movement Disorders 2018, 33: 697-700. PMID: 29722454, DOI: 10.1002/mds.27398.Peer-Reviewed Original Research
1991
L-Deprenyl (Selegiline) Added to Sinemet CR in the Management of Parkinson's Disease Patients With Motor Response Fluctuations.
Cedarbaum JM, Toy LH, Green-Parsons A. L-Deprenyl (Selegiline) Added to Sinemet CR in the Management of Parkinson's Disease Patients With Motor Response Fluctuations. Clinical Neuropharmacology 1991, 14: 228. PMID: 1906374, DOI: 10.1097/00002826-199106000-00005.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntiparkinson AgentsCarbidopaDrug CombinationsDrug Therapy, CombinationHumansLevodopaMiddle AgedMovementParkinson DiseaseSelegilineTime FactorsConceptsSinemet CRParkinson's diseaseResponse fluctuationsDisease patientsL-deprenylMean interdose intervalTherapeutic response fluctuationsAdvanced Parkinson's diseaseMotor response fluctuationsParkinson's disease patientsLevodopa intakeMotor fluctuationsInterdose intervalTreatment regimensPatientsSignificant reductionDeprenylDiseaseRegimensDyskinesiaImproved control
1990
Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR)
Cedarbaum JM, Silvestri M, Clark M, Toy L, Harts A, Green-Parsons A, McDowell FH. Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR). Journal Of Neural Transmission: Parkinson's Disease A And Dementia Section 1990, 2: 205-213. PMID: 2257060, DOI: 10.1007/bf02257651.Peer-Reviewed Original ResearchConceptsStandard SinemetMotor response fluctuationsResponse fluctuationsSinemet CRDisease patientsControlled-release levodopa/carbidopaLevodopa/carbidopaLong-term treatmentParkinson's disease patientsLong-term managementAntiparkinson effectEligible patientsMost patientsMedication dosesInterdose intervalClinical trialsParkinson's diseaseUseful adjunctPatientsSinemetDiseaseYearsCarbidopaAdjunctDoseSustained‐release (+)‐PHNO [MK‐458 (HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2‐receptor agonist administered as a long‐acting formulation
Cedarbaum J, Clark M, Toy L, Green‐Parsons A. Sustained‐release (+)‐PHNO [MK‐458 (HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2‐receptor agonist administered as a long‐acting formulation. Movement Disorders 1990, 5: 298-303. PMID: 1979657, DOI: 10.1002/mds.870050407.Peer-Reviewed Original ResearchConceptsMK-458Disease patientsSelective D2 receptor agonistPostsynaptic dopamine receptorsMotor response fluctuationsD2 receptor agonistParkinson's disease patientsSustained-release formAdjunctive therapyD2 agonistDopamine receptorsSinemetParkinson's diseaseAgonistsResponse fluctuationsProgressive lossPatientsWeeksDiseaseDosageReduced sensitivityDaysTherapyReceptors
1989
A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
Cedarbaum JM, Kutt H, McDowell FH. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). Neurology 1989, 39: 38-44; discussion 59. PMID: 2586762.Peer-Reviewed Original ResearchMeSH KeywordsAntiparkinson AgentsCarbidopaDrug CombinationsFemaleHumansLevodopaMaleMiddle AgedParkinson DiseaseTyrosineConceptsSinemet CRLevodopa levelsNew controlled-release formulationStandard Sinemet 25/100Advanced Parkinson's diseasePlasma levodopa levelsBioavailability of levodopaClinical observation studyAntiparkinsonian effectsLevodopa intakeSinemet 25/100Standard SinemetPharmacodynamic comparisonMedication dosesInterdose intervalParkinson's diseaseCR preparationControlled-release formulationLevodopaMotor performanceCarbidopaObservation studyDiseaseProlongationSinemet
1988
Controlled-Release Levodopa/Carbidopa III: Sinemet CR5 Treatment of Response Fluctuations in Parkinson's Disease.
Cedarbaum JM, Hoey M, Kutt H, McDowell FH. Controlled-Release Levodopa/Carbidopa III: Sinemet CR5 Treatment of Response Fluctuations in Parkinson's Disease. Clinical Neuropharmacology 1988, 11: 168. PMID: 3378225, DOI: 10.1097/00002826-198804000-00008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntiparkinson AgentsBiological AvailabilityCarbidopaDelayed-Action PreparationsDrug CombinationsDrug EvaluationHumansLevodopaParkinson DiseaseConceptsSinemet CR4Parkinson's diseasePeak plasma levodopa concentrationResponse fluctuationsOpen-label studyAdvanced Parkinson's diseasePlasma levodopa concentrationsStandard SinemetInterdose intervalDaily dosesTherapeutic responseLevodopa concentrationsSame patientLabel studyDiseaseRelative bioavailabilityPatientsGreater delayTreatmentSinemetLevodopaDoses
1987
Clinical Pharmacokinetics of Anti-Parkinsonian Drugs
Cedarbaum J. Clinical Pharmacokinetics of Anti-Parkinsonian Drugs. Clinical Pharmacokinetics 1987, 13: 141-178. PMID: 3311529, DOI: 10.2165/00003088-198713030-00002.Peer-Reviewed Original ResearchConceptsAnti-parkinsonian agentsAnti-parkinsonian drugsClinical PharmacokineticsParkinson's diseaseDirect acting dopamine receptor agonistsLarge neutral amino acidsResponse fluctuationsAnti-parkinsonian actionLittle pharmacokinetic dataPharmacodynamics of levodopaTherapeutic response fluctuationsPlasma levodopa concentrationsDopamine receptor agonistsPotential drug toxicityClass of drugsMechanism of actionParkinsonian populationRenal functionPharmacokinetic considerationsUnchanged drugBrain uptakeReceptor agonistRenal excretionShort eliminationLevodopa concentrationsControlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
Cedarbaum J, Breck L, Kutt H, McDowell F. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease. Neurology 1987, 37: 233-41. PMID: 3808304, DOI: 10.1212/wnl.37.2.233.Peer-Reviewed Original ResearchConceptsPlasma levodopa levelsLevodopa levelsResponse fluctuationsParkinson's diseaseControlled-release carbidopa/levodopaCarbidopa/levodopaOpen-label trialBioavailability of levodopaStandard SinemetDisability scoresLevodopa preparationsInterdose intervalDaily dosesParkinson's patientsControlled-release formulationClinical performanceDiseaseLevodopaDay consistencyOverall benefitSinemetPatientsDosesTrialsWeeks